Anticoagulant

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
1 program
acenocoumarolN/A2 trials
Active Trials
NCT03154489Completed204Est. Sep 2019
NCT01851824Completed9Est. Jun 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rocheacenocoumarol
Rocheacenocoumarol

Clinical Trials (2)

Total enrollment: 213 patients across 2 trials

NCT01851824Rocheacenocoumarol

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Start: Aug 2013Est. completion: Jun 20149 patients
Phase 1Completed
NCT03154489Rocheacenocoumarol

Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care

Start: May 2017Est. completion: Sep 2019204 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space